Cigarette smoking is the first risk factor for lung cancer and one of the leading causes of...
Diagnostic Imaging and Radiotherapy
Director of Radiotherapy and Radiosurgery Department
Education and Academic Background
2013-now: Member of Ethical Committee of National Cancer Institute of Milan.
2009-2012: Member of Board of Directors of FONICAP (Interdisciplinary National Operative Force Against Lung Cancer.
2011-2014: Member of Board of Directors of AIRO (Italian Association of Radiation Oncology).
2010-2012: Coordinator of AIRO lung cancer work group.
2008-2010: Coordinator of AIRO SBRT work group.
- Italian Association of Radiotherapy (AIRO)
- European Society for Radiotherapy & Oncology (ESTRO)
- Interdisciplinary National Operative Force Against Lung Cancer (FONICAP)
- International Association for the Study of Lung Cancer (IALSC) and European Association of Neuro –Oncology ( EANO)
Scientific and Research Interests
Prof. Marta Scorsetti has a major role in the development of Radiosurgery, Stereotactic Body Radiation Therapy (SBRT) and Volumetric modulated Arc Therapy (VMAT). With her experience in these radiotherapy techniques, Prof. Scorsetti has contributed to the Humanitas Cancer Center in becoming a referral Hospital for the treatment of liver tumors, pancreatic cancer and lung neoplasm.
She graduated from the University of Milan, Faculty of Medicine, in 1993. In 1998 Prof. Marta Scorsetti obtained her post-graduate degree in Radiology and Radiation Oncology. From 1999 to 2003 she worked at the National Cancer Institute of Milan, as Assistant Radiation Oncologist and subsequently Associate Chief in Radiation Oncology. Her main interests, activities and responsibilities are radiobiology and physics, new approaches in radiation treatment planning, integrated treatments (radio -chemotherapy in solid tumors), implementation of highly conformal radiation therapy techniques, as Radiosurgery and SBRT. Since 2002 Prof. Marta Scorsetti has been adjunct professor in Radiation Oncology for the University of Milan. She has been Director of Radiotherapy and Radiosurgery department at Humanitas Research Hospital since 2003. She also tutored residents in Radiation Oncology, Thoracic and General Surgery, Diagnostic Imaging and Radiotherapy and Medical Oncologist at the University of Milan and at Humanitas University.
Prof. Scorsetti has been Associate professor in Diagnostic Imaging and Radiotherapy at Humanitas University since March 2016.
Prof. Marta Scorsetti is principal investigator in clinical trials for the development of SBRT in lung cancer, pancreatic tumors, metastasis and primary tumors of the liver, oligometastatic patients in different settings including abdominal metastases (lymph-nodes and adrenal) and lung metastasis, prostate cancer, and Radiosurgery for brain metastasis. She is also investigator in several trials of hypofractionation in breast cancer and primary brain tumors.
She has published more than 100 scientific papers in international peer-reviewed journals, several books chapters, edited/reviewed for many academic journals.
- Scorsetti M, Franceschini D, De Rose F, et al. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast. 2016 Apr;26:11-7
- Comito T, Cozzi L, […], Scorsetti M. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technol Cancer Res Treat. 2016 Jun 16
- Scorsetti M, Alongi F, Clerici E, et al. Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. J Cancer Res Clin Oncol. 2014 Oct;140(10):1795-800
- Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):336-42
- Navarria P, Ascolese AM, Mancosu P, et al. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol. 2013 Jun;107(3):414-8